<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800014601</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-01-23</date_registration>
      <primary_sponsor>the First Affiliated Hospital of Guangxi Medical University</primary_sponsor>
      <public_title>Autologous bone marrow derived stem cells in the treatment of intrauterine adhesions and thin endometrium</public_title>
      <acronym />
      <scientific_title>Autologous bone marrow derived stem cells in the treatment of intrauterine adhesions and thin endometrium</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-02-01</date_enrolment>
      <type_enrolment />
      <target_size>BSC:20;G-GSF group:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=24043</url>
      <study_type>Observational study</study_type>
      <study_design>Cohort study</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Asherman's syndrome and thinned endometrium</hc_freetext>
      <i_freetext>BSC:BSC perfusion;G-GSF group:G-GSFperfusion;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Hang Fu</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong Road, Nanning, Guangxi, China</address>
        <city />
        <country1 />
        <zip>530021</zip>
        <telephone>+86 13978628631</telephone>
        <email>hangfu@yahoo.com</email>
        <affiliation>the First Affiliated Hospital of Guangxi Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Qin Aiping</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong Road, Nanning, Guangxi, China</address>
        <city />
        <country1 />
        <zip>530021</zip>
        <telephone>+86 13977102456</telephone>
        <email>aini02456@126.com</email>
        <affiliation>the First Affiliated Hospital of Guangxi Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Age 20-40 years-old;
2. Previous hysteroscopy diagnosis of intrauterine adhesions, thinned endometrium or  endometrial atrophy;
3. previously endometrium thickness ≤5mm during  pre-ovulatory phase of natural cycle or hormone replacement therapy (HRT)cycle;
4. Normal liver, heart and kidney function;
5. Absence of psychiatric pathology and ability to accomplish the treatment;
6. β-hCG negative;
7. Absence of STDs, hepatitis B or hepatitis C;
8. At least 2 high quality D3 embryos available for ET;
9. willingness to join and complete this study.</inclusion_criteria>
      <agemin>20</agemin>
      <agemax>40</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1. Acute urogenital infection;
2. Combined with other genital disease ingcluding hysteromyoma, adenomyosis, hydrosalpinx or other chronic disease that incapable for pregnancy;
3. Allergy to G-CSF or contraindication to G-CSF.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Endometrial thickness;Endometrial blood flow;Biochemical pregnancy rate;Clinical pregnancy rate;Continue the pregnancy rate;Miscarriage rate;Endometrial shape;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-funding</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-12-29</approval_date>
        <contact_name>huangfeng</contact_name>
        <contact_address>The First Affiliated Hospital of Guangxi Medical University</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>